Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: Survival analysis in 210 patients

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 1789-1803

  Fan, Yun ^a   Huang, Zhiyu ^a   Fang, Luo ^a   Miu, Lulu ^a   Lin, Nengming ^a   Gong, Lei ^a   Yu, Haifeng ^a   Yang, Haiyan ^a   Mao, Weimin ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Brain metastases; Chemotherapy; Epidermal growth factor receptor; Non small cell lung cancer; Pemetrexed; Tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PEMETREXED;

ADULT; AGE; AGED; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EGFR GENE; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RETROSPECTIVE STUDY; SURVIVAL TIME; YOUNG ADULT;

EID: 84889261182     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S52172     Document Type: Article

References (40)

1. Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases. Arch Neurol. 1988;45(7):741-744.
2. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 2005;23(25):6207-6219.
3. Patchell RA. Brain metastases. Neurol Clin. 1991;9(4):817-824.
4. Gaspar LE, Mehta MP, Patchell RA, etal. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):17-32.
5. Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol. 2006;24(8): 1295-1304.
6. Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist. 2007;12(7):884-898.
7. Antonadou D, Paraskevaidis M, Sarris G, etal. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol. 2002;20(17):3644-3650.
8. Chua D, Krzakowski M, Chouaid C, etal. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study. Clin Lung Cancer. 2010;11(3):176-181.
9. Cortes J, Rodriguez J, Aramendia JM, etal. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology. 2003;64(1):28-35.
10. Guerrieri M, Wong K, Ryan G, etal. A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer. 2004;46(1): 107-111.
11. Ushio Y, Arita N, Hayakawa T, etal. Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study. Neurosurgery. 1991;28(2):201-205.
12. Verger E, Gil M, Yaya R, etal. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys. 2005;61(1): 185-191.
13. Bearz A, Garassino I, Tiseo M, etal. Activity of pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer. 2010;68(2): 264-268.
14. Ceresoli GL, Cappuzzo F, Gregorc V, etal. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol. 2004;15(7):1042-1047.
15. Kim JE, Lee DH, Choi Y, etal. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer. 2009;65(3):351-354.
16. Namba Y, Kijima T, Yokota S, etal. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer. 2004;6(2):123-128.
17. Wu C, Li YL, Wang ZM, etal. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer. 2007;57(3): 359-364.
18. Wu YL, Zhou C, Cheng Y, etal. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol. 2013;24(4):993-999.
19. Newton CR, Graham A, Heptinstall LE, etal. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17(7):2503-2516.
20. Gaspar L, Scott C, Rotman M, etal. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745-751.
21. Gaspar LE, Scott C, Murray K, Curran W. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys. 2000;47(4):1001-1006.
22. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70(2):510-514.
23. Zimm S, Wampler GL, Stablein D, Hazra T, Young HF. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer. 1981;48(2):384-394.
24. Ruderman NB, Hall TC. Use of glucocorticoids in the palliative treatment of metastaic brain tumors. Cancer. 1965;8:298-306.
25. Moscetti L, Nelli F, Felici A, etal. Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology. Cancer. 2007;109(2): 274-281.
26. Robinet G, Thomas P, Breton JL, etal. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-91. Ann Oncol. 2001;12(1): 59-67.
27. Barlesi F, Gervais R, Lena H, etal. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol. 2011;22(11):2466-2470.
28. Welsh JW, Komaki R, Amini A, etal. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013;31(7): 895-902.
29. Matsumoto S, Takahashi K, Iwakawa R, etal. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer. 2006;119(6):1491-1494.
30. Mok TS, Wu YL, Thongprasert S, etal. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10): 947-957.
31. Porta R, Sanchez-Torres JM, Paz-Ares L, etal. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2011;37(3):624-631.
32. Park SJ, Kim HT, Lee DH, etal. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 2012;77(3):556-560.
33. Ma S, Xu Y, Deng Q, Yu X. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and gefitinib in a Chinese population. Lung Cancer. 2009;65(2):198-203.
34. Broniscer A, Panetta JC, O'Shaughnessy M, etal. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res. 2007;13(5):1511-1515.
35. Zhao J, Chen M, Zhong W, etal. Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cancer. 2013;14(2):188-193.
36. Dai H, Chen Y, Elmquist WF. Distribution of the novel antifolate pemetrexed to the brain. J Pharmacol Exp Ther. 2005;315(1): 222-229.
37. Sanghavi SN, Miranpuri SS, Chappell R, etal. Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys. 2001;51(2):426-434.
38. Frazier JL, Batra S, Kapor S, etal. Stereotactic radiosurgery in the management of brain metastases: an institutional retrospective analysis of survival. Int J Radiat Oncol Biol Phys. 2010;76(5):1486-1492.
39. Sperduto PW, Chao ST, Sneed PK, etal. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655-661.
40. Sperduto PW, Kased N, Roberge D, etal. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419-425.